关注
Naga Duggirala
Naga Duggirala
Principal Scientist at Pfizer
在 pfizer.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Polymorphs, salts, and cocrystals: what’s in a name?
S Aitipamula, R Banerjee, AK Bansal, K Biradha, ML Cheney, ...
Crystal growth & design 12 (5), 2147-2152, 2012
11382012
Pharmaceutical cocrystals: along the path to improved medicines
NK Duggirala, ML Perry, Ö Almarsson, MJ Zaworotko
Chemical communications 52 (4), 640-655, 2016
9672016
Improving lithium therapeutics by crystal engineering of novel ionic cocrystals
AJ Smith, SH Kim, NK Duggirala, J Jin, L Wojtas, J Ehrhart, B Giunta, ...
Molecular pharmaceutics 10 (12), 4728-4738, 2013
1082013
Physical stability enhancement and pharmacokinetics of a lithium ionic cocrystal with glucose
NK Duggirala, AJ Smith, Ł Wojtas, RD Shytle, MJ Zaworotko
Crystal growth & design 14 (11), 6135-6142, 2014
912014
Hydrogen bond hierarchy: persistent phenol··· chloride hydrogen bonds in the presence of carboxylic acid moieties
NK Duggirala, GPF Wood, A Fischer, Ł Wojtas, ML Perry, MJ Zaworotko
Crystal Growth & Design 15 (9), 4341-4354, 2015
632015
Mechanistic insight into caffeine–oxalic cocrystal dissociation in formulations: Role of excipients
NK Duggirala, A Vyas, JF Krzyzaniak, KK Arora, R Suryanarayanan
Molecular pharmaceutics 14 (11), 3879-3887, 2017
462017
Pharmaceutical cocrystals: formulation approaches to develop robust drug products
NK Duggirala, SM LaCasse, MJ Zaworotko, JF Krzyzaniak, KK Arora
Crystal Growth & Design 20 (2), 617-626, 2019
412019
Role of lattice disorder in water-mediated dissociation of pharmaceutical cocrystal systems
N Kaur, NK Duggirala, S Thakral, R Suryanarayanan
Molecular pharmaceutics 16 (7), 3167-3177, 2019
302019
A supramolecular synthon approach to design amorphous solid dispersions with exceptional physical stability
NK Duggirala, J Li, NSK Kumar, T Gopinath, R Suryanarayanan
Chemical Communications 55 (39), 5551-5554, 2019
282019
Solid-State characterization and relative formation enthalpies to evaluate stability of cocrystals of an antidiabetic drug
NK Duggirala, HL Frericks Schmidt, Z Lei, MJ Zaworotko, JF Krzyzaniak, ...
Molecular Pharmaceutics 15 (5), 1901-1908, 2018
122018
Design of ternary amorphous solid dispersions for enhanced dissolution of drug combinations
J Li, NK Duggirala, NSK Kumar, Y Su, R Suryanarayanan
Molecular pharmaceutics 19 (8), 2950-2961, 2022
112022
Dual Functionality of Bile Acid: Physical Stabilization of Drugs in the Amorphous Form and Solubility Enhancement in Solution
R Lalge, N Kaur, NK Duggirala, R Suryanarayanan
Molecular pharmaceutics 19 (7), 2595-2606, 2022
102022
Phase behavior of poloxamer 188 in frozen aqueous solutions–Influence of processing conditions and cosolutes
NK Duggirala, J Sonje, X Yuan, E Shalaev, R Suryanarayanan
International journal of pharmaceutics 609, 121145, 2021
102021
Formation of indomethacin–saccharin cocrystals during wet granulation: role of polymeric excipients
R Tanaka, NK Duggirala, Y Hattori, M Otsuka, R Suryanarayanan
Molecular pharmaceutics 17 (1), 274-283, 2019
102019
Polytypism in desvenlafaxine succinate monohydrate
NK Duggirala, SL Kanniah, VK Muppidi, R Thaimattam, S Devarakonda
CrystEngComm 11 (6), 989-992, 2009
92009
Lenalidomide solvates and processes
S Rangineni, N Duggirala, VK Mudapaka, R Kadaboina, V Murki, ...
US Patent App. 13/109,232, 2011
22011
Amorphous pemetrexed disodium
R Kadaboina, SM Nariyam, S Ramakrishnan, S Peddireddy, MA Baig, ...
US Patent App. 13/042,867, 2011
22011
Crystal form comprising lithium ions, pharmaceutical compositions thereof, methods for preparation and their uses for the treatment of depressive disease
M Zaworotko, M Perry, RL Carneiro, N Duggirala, D O'nolan, P Krishna
US Patent App. 16/097,444, 2019
12019
Organic anion lithium ionic cocrystal compounds and compositions
MJ Zaworotko, N Duggirala, AJ Smith, RD Shytle
US Patent 9,840,521, 2017
12017
Process for preparation of celecoxib crystalline form
VK Muppidi, S Rangineni, NK Duggirala, S Ramakrishnan, AK Tummala
US Patent App. 13/036,848, 2011
12011
系统目前无法执行此操作,请稍后再试。
文章 1–20